Breaking News

You are here » Indian-Commodity  :  Corporate  :  Indiabulls Housing raises Rs 800 crore via NCDs

17-Aug2016

Indiabulls Housing raises Rs 800 crore via NCDs

Indiabulls Housing Finance has raised Rs 800 crore by issuing non convertible debentures (NCDs) on a private placement basis. The issue closed on August 16 and the bonds will carry coupon rate of 8.80 per cent (payable annually and at maturity). Date of maturity of debentures is August 16, 2021.

Indiabulls Housing Finance is the second largest private housing finance company in India, regulated by the National Housing Bank (NHB).


Related News

View all news

IndiGo planning to launch one-stop flights to Europe: Report

InterGlobe Aviation (IndiGo) is reportedly planning to launch flights to London and other European cities by single stop. The airline is in talks with the airports in Tbilisi which is in Georgia and Baku......

Reliance Infrastructure reports 49% fall in Q2 consolidated net profit

Reliance Infrastructure has reported results for second quarter ended September 30, 2018.The company has reported a fall of 65.66% in its net profit at Rs 204.31 crore for the quarter under review as compared......

Shilpa Medicare gets tentative ANDA approval for Dimethyl Fumarate DR Capsules

Shilpa Medicare has received tentative approval for its ANDA for Dimethyl Fumarate Delayed Release Capsules 120 mg & 240 mg. from USFDA. Dimethyl Fumarate Delayed Release Capsules 120 mg &......

Top News

View all news

Karnataka Bank launches CASA campaign

Karnataka Bank has launched Current & Savings Accounts campaign (CASA) of FY 2018-19 and introduced a new SB scheme 'KBL SB - TASC' a specialized product for Trusts/Associates/Societies/Clubs.Under......

M&M's arm opens manufacturing hub in Bengaluru

Mahindra & Mahindra's (M&M) subsidiary -- Mahindra Electric Mobility has opened its electric technology manufacturing hub set up with an investment of Rs 100 crore in Bengaluru. The plant......

Venus Remedies reports positive result in Phase-3 Clinical Trials for ELORES

Venus Remedies has reported positive Top-Line results in its Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific......